PetVivo Ends VetStem License, Settles Disputes for $75K

summarizeSummary

PetVivo terminated its license agreement with VetStem, paying $75,000 to settle all disputes and returning PrecisePRP inventory. The move eliminates legal uncertainty and allows focus on core products, but the company remains under financial pressure.

check_boxKey Events · Legal and Risk Events · PETV

• License Agreement Terminated

  Effective July 24, 2026, PetVivo and VetStem mutually terminated their Exclusive License and Supply Agreement, ending PetVivo's rights to the PrecisePRP product line.

• Settlement Payment of $75,000

  To fully settle all disputes and extinguish prior financial obligations, PetVivo will pay $75,000 in two installments: $50,000 within 14 days and $25,000 within 30 business days.

• Inventory Returned to VetStem

  All remaining PrecisePRP inventory—at least 1,828 vials—transfers to VetStem at no cost; PetVivo may owe additional fees if the inventory count falls short.

• Warrant Remains Outstanding

  The previously issued warrant allowing VetStem to purchase 250,000 shares of PetVivo common stock remains in full force and effect, representing potential future dilution.

auto_awesomeAnalysis · PETV · Industrial Applications And Services

By terminating its exclusive license for the PrecisePRP product line, PetVivo has resolved all disputes with VetStem. The settlement requires a $75,000 payment and the return of inventory, though a warrant for 250,000 shares remains outstanding. Removing this legal overhang allows management to concentrate on its proprietary SPRYNG technology, but it also means surrendering a commercialized product line. The cost is modest relative to the company's financial distress—the recent 10-K flagged going concern risk and material weaknesses—so clearing this distraction is a small positive step, though it doesn't address the core cash burn problem.